Cardiac Amyloidosis: Everywhere, but Nowhere

Cardiac Amyloidosis: Everywhere, but Nowhere In the past decade, there has been increasing interest surrounding cardiac amyloidosis (CA), partly due to the availability of effective therapies for transthyretin CA (ATTR-CA).1,2 Unfortunately, such progress has been largely limited to developed countries, with little to no progress seen in countries like Malaysia. In fact, clinical pathways in the initial evaluation and management of CA remain sparse in Malaysia, although... Cardiac Amyloidosis: Everywhere, but Nowhere In the past decade, there has been increasing interest surrounding cardiac amyloidosis (CA), partly due to the availability of effective therapies for transthyretin CA (ATTR-CA).1,2 Unfortunately, such progress has been largely limited to developed countries, with little to no progress seen in countries like Malaysia. In fact, clinical pathways in the initial evaluation and management of CA remain sparse in Malaysia, although...
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research